← Back

Slovenia JAZMP · Slovenia · 8 Oct 2026 · Safety alert & recall

Ocrevus (ocrelizumab): Direct Healthcare Professional Communication on new hepatic safety risk

Original title: Ocrevus (okrelizumab): obvestilo za zdravstvene delavce

Read at Slovenia JAZMP ↗
Pharmaceuticals
AI-generated summary

Ocrevus (ocrelizumab) carries a new hepatic risk, and the Slovenian medicines agency JAZMP has published a Direct Healthcare Professional Communication with recommendations for monitoring liver function before and during treatment with this medicine.

From Slovenia JAZMP

Zdravstvene delavce obveščamo, da je na spletni strani JAZMP objavljeno neposredno obvestilo (angl. DHPC – Direct Healthcare Professional Communication) o novem tveganju za z zdravilom Ocrevus (okrelizumab) povzročeno okvaro jeter in priporočilih glede spremljanja delovanja jeter pred in med zdravljenjem. Obvestilo je dostopno na naslednji povezavi.

Excerpt from the official page. The original is authoritative.